Clinically-oriented phenotypic screening: understanding and exploiting the dynamic nature of the cancer cell phenotype
Understanding the cancer cell phenotype is central to both cancer diagnosis and treatment. Discrete molecular signatures among cancer phenotypes underpin patient stratification, while rapid methods for detailed phenotyping in the clinic (via liquid biopsies and tumour imaging) enable the delivery of personalised, effective precision medicines to the cancer patient…
Here, briefly, we describe how emerging data are defining molecular phenotypes among specific cancer cell lineages, and how these can be used in phenotypic screening to discover and profile drugs which modulate them. We focus on recent advances in molecular phenotyping for human glioma and its high-grade counterpart, glioblastoma multiforme (GBM), and review how laboratory advances for glioma are translating to the clinic.
The rest of this article is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!